FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person +	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer
		(Check all applicable)
Zhang Jack Y.	Amphastar Pharmaceuticals, Inc. [
	AMPH]	_X_Director _X_10% Owner
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	_X_ Officer (give title below) Other (specify below)
		CEO & Chief Scientific Officer
C/O AMPHASTAR	5/18/2022	
PHARMACEUTICALS, INC., 11570		
6TH STREET		
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)
RANCHO CUCAMONGA, CA 91730 (City) (State) (Zip)		Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

				· · ·)	- P		including Owned		_
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Co (Instr. 8)	ode	4. Securi Disposed (Instr. 3,	l of (D)	uired (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Direct (D)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price		or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock	5/18/2022		S (1)		55264	D	\$33.9714 (2)	2168305	D	
Common Stock	5/18/2022		S ⁽¹⁾		9776	D	\$34.7715 (<u>3)</u>	2158529	D	
Common Stock	5/18/2022		S ⁽¹⁾		2006	D	\$35.7822 ⁽⁴⁾	2156523	D	
Common Stock	5/19/2022		S (1)		41615	D	\$33.7575 (<u>5</u>)	2114908	D	
Common Stock	5/19/2022		S ⁽¹⁾		115	D	\$34.28	2114793	D	
Common Stock								1498519		See footnote <mark>(6</mark>)
Common Stock								6827679		See footnote ⁽⁷⁾
Common Stock								5000		See footnote ⁽⁸⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

								······			··· , • P ··· ··· , • • ··· · •				
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. C (Instr. 8)		5. Number Derivative Acquired (A Disposed o (Instr. 3, 4 a)	Securities A) or f (D)	6. Date Exer and Expirati	ion Date	Secur Deriv	ities Underlying ative Security	Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	Ownership Form of Derivative	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect (I) (Instr. 4)	

Explanation of Responses:

- (1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.44 to \$34.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.
- (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.45 to \$35.44, inclusive.
- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.45 to \$36.15, inclusive.
- (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.27 to \$34.24, inclusive.
- (6) The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
- (7) The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons and The Bill Luobei Zhang 2004 Irrevocable

Trust are the sole owners.

(8) The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaim beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.

Reporting Owners

Reporting Owner Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Zhang Jack Y. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	x	X	CEO & Chief Scientific Officer	ŗ		
Luo Mary Z. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	x	X	CEO & Chief Scientific Officer			

Signatures

/s/ Eva Wen, by power of attorney for Jack Y. Zhang	5/20/2022
**Signature of Reporting Person	Date
/s/ Eva Wen, by power of attorney for Mary Z. Luo	5/20/2022
	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.